[1]李苗苗 赵晖 廖星 王永炎.卫生技术评估和循证医学的决策协同逻辑与实践路径研究[J].中国卫生质量管理,2025,32(06):001-5.[doi:10.13912/j.cnki.chqm.2025.32.6.01]
　LI Miaomiao,ZHAO Hui,LIAO Xing.Research on the Decision-Making Synergy Logic and Practical Pathways of Health Technology Assessment and Evidence-Based Medicine[J].Chinese Health Quality Management,2025,32(06):001-5.[doi:10.13912/j.cnki.chqm.2025.32.6.01]
点击复制

卫生技术评估和循证医学的决策协同逻辑与实践路径研究()
分享到：

《中国卫生质量管理》[ISSN:1006-7515/CN:CN 61-1283/R]

卷:
第32卷
期数:
2025年06期
页码:
001-5
栏目:
特别关注
出版日期:
2025-06-15

文章信息/Info

Title:
Research on the Decision-Making Synergy Logic and Practical Pathways of Health Technology Assessment and Evidence-Based Medicine
作者:
李苗苗 赵晖 廖星 王永炎
中国中医科学院中医临床基础医学研究所
Author(s):
LI Miaomiao;  ZHAO Hui;  LIAO Xing
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
关键词:
卫生技术评估;  循证医学; 比较效益研究; 动态卫生技术评估
Keywords:
Health Technology Assessment;  Evidence-Based Medicine; Comparative Effectiveness Research; Living-Health Technology Assessment
分类号:
R197.32；R4
DOI:
10.13912/j.cnki.chqm.2025.32.6.01
文献标志码:
A
摘要:
从发展脉络、理论演进、交互逻辑、方法学整合以及应用挑战与对策等方面探讨卫生技术评估（HTA）和循证医学（EBM）的决策协同逻辑与实践路径。HTA通过多维度评估为EBM提供全面的证据，而EBM可通过临床实践验证HTA的评估结果。尽管HTA与EBM在方法学设计、临床实践、政策制订等方面存在挑战，但它们的结合能够为医疗决策提供更全面的证据。未来应制订统一的评估标准和流程，搭建信息共享平台，促进HTA和EBM协同应用，以优化医疗决策，提高卫生资源利用率。
Abstract:
This paper explores the decision-making synergy logic and practical pathways between Health Technology Assessment (HTA) and Evidence-Based Medicine (EBM) from aspects such as development context, theoretical evolution, interactive logic, methodological integration, as well as application challenges and countermeasures. HTA provides comprehensive evidence for EBM through multi-dimensional assessment, while EBM validates the assessment results of HTA through clinical practice. Despite challenges in methodological design, clinical practice, policy formulation, and other areas, the combination of HTA and EBM can provide a more comprehensive basis for medical decision-making. In the future, unified evaluation standards and processes should be established, and information-sharing platforms should be built to promote the synergistic application of HTA and EBM, thereby optimizing medical decision-making and improving the utilization rate of health resources.

参考文献/References:

［1］O’REILLY D, AUDAS R, CAMPBELL K, et al. Evidence-based decision making 3: health technology assessment［J］. Methods Mol Biol, 2021(2249):429-454. ［2］李 薇,韩 晟,陈英耀.“Living HTA”的概念、方法与挑战［J］.中国卫生经济,2024,43(8):1-4.［3］CHLOROS GD, PRODROMIDIS AD, GIANNOUDIS PV. Has anything changed in evidence-based medicine?［J］. Injury,2023,54:20-25.［4］EDDY DM. Evidence-based medicine: a unified approach［J］.Health Affairs，2005, 24(1):9-17.［5］EDDY D. Health technology assessment and evidence-based medicine: what are we talking about?［J］. Value in Health,2009,12:6-7.［6］LUCE BR, DRUMMOND M, JNSSON B, et al. EBM, HTA and CER: clearing the confusion［J］. Milbank Q，2010,88(2):256-276. ［7］李 静,李幼平,刘 鸣.卫生技术评估与循证医学［J］.华西医学,2000,15(1):6-9.［8］廖 星,郭武栋,曹 庄,等. 应用卫生技术评估开展中成药临床综合评价［J］. 中国中药杂志, 2020, 45(16):3749-3758.［9］CHEN Y, HE Y, CHI X, et al. Development of health technology assessment in China: new challenges［J］. BioScience Trends,2018,12(2):102-108.［10］王海银,孙 辉,王昊德,等.价值重塑下的我国卫生技术评估发展与展望［J］.中国卫生质量管理,2022,29(6):1-3，8.［11］O’ROURKE B, OORTWIJN W, SCHULLER T. The new definition of health technology assessment: a milestone in international collaboration［J］. Int J Technol Assess Health Care，2020，36(3):187-190.［12］廖 星,谢雁鸣,田 峰,等. 比较效益研究的设计、实施和分析方法概述［J］.中国中药杂志, 2013, 38 (6): 930-935.［13］谢雁鸣,廖 星.对比较效益研究GRACE准则的解析［J］.中国中西医结合杂志, 2012, 32 (8): 1121-1125.［14］谢雁鸣,廖 星,王永炎. 将比较效益研究理念引入中医临床评价研究［J］.中西医结合学报, 2011, 9 (8): 813-818.［15］CHANDRA A, JENA AB, SKINNER JS. The pragmatist’s guide to comparative effectiveness research［J］. J Econ Perspect，2011，25(2):27-46. ［16］DJULBEGOVIC B, GUYATT GH. Progress in evidence-based medicine: a quarter century on［J］. Lancet, 2017, 390(10092):415-423. ［17］SUBBIAH V. The next generation of evidence-based medicine［J］. Nature Medicine,2023,29(1): 49-58.［18］MERLIN T. Decisions in health technology assessment: should we speak with one voice?［J］. Health Res Policy Syst, 2018,16(1):108. ［19］耿劲松,唐 密,杨 海,等.医院卫生技术评估研究方法的循证分析［J］.中国卫生质量管理, 2024, 31(12): 1-6.［20］EDDY D,郑亚明，吴晶.卫生技术评估与循证医学:我们研究的是什么?［J］.中国药物经济学, 2010(1):66-69.［21］MOHAMAD NF, MANSOR Z, MAHMUD A, et al. Preparing future doctors for evidence-based practice: a study on health technology assessment awareness and its predictors in Malaysia［J］. International Journal of Technology Assessment in Health Care,2024,40(1):e18.［22］SHI L, MAO Y, TANG M, et al. Health technology assessment in China: challenges and opportunities［J］. Global Health Journal, 2017,1:11-20. ［23］KRITTANAWONG C, JOHNSON KW, TANG WW. How artificial intelligence could redefine clinical trials in cardiovascular medicine: lessons learned from oncology［J］. Per. Med, 2019,16: 83-88.［24］PESSOA-AMORIM G, CAMPBELL M, FLETCHER L,et al.Making trials part of good clinical care: lessons from the RECOVERY trial［J］. Future Healthc J, 2021,8(2):243-250. ［25］戴泽琦. 基于EVIDEM（证据和价值）框架建立中成药临床综合评价方法的研究［D］. 北京：中国中医科学院, 2023. ［26］廖 星,戴泽琦,吴 雪,等. 采用EVIDEM框架开展中成药临床综合评价［J］.中国中药杂志, 2022, 47 (10): 2833-2840. ［27］胡 晶,周甜甜,阮 岩,等. 金嗓散结丸/胶囊治疗声带小结、声带息肉的临床综合评价［J］.中国中药杂志, 2023, 48 (23): 6278-6284. ［28］LIU G, WU EQ, AHN J, et al. The development of health technology assessment in Asia: current status and future trends［J］. Value Health Reg Issues, 2020,21:39-44.［29］WANG H, JIN C, BAI F, et al. Driving factors and mode transformation regarding health technology assessment (HTA) in China: problems and recommendations［J］. Biosci Trends, 2019,13:110-116.

相似文献/References:

[1]唐檬,陈英耀,茅艺伟,等.中国卫生技术评估决策转化现状及影响因素的定性研究[J].中国卫生质量管理,2015,22(06):095.
[2]王海银 张晓溪 房良 金春林.我国卫生技术评估流程规范研究[J].中国卫生质量管理,2016,23(06):060.[doi:10.13912/j.cnki.chqm.2016.23.6.21]
[3]魏巍 张涛 鱼敏.便携式早期清创冲洗器的卫生技术评估[J].中国卫生质量管理,2018,25(03):079.[doi:10.13912/j.cnki.chqm.2018.25.3.24]
[4]张曙欣 陈校云 冯力 宋杨杨 胡可慧 黄婉茹 裴治纲.澳大利亚和新西兰新兴卫生技术水平扫描网络的实践与启示[J].中国卫生质量管理,2019,26(02):106.[doi:10.13912/j.cnki.chqm.2019.26.2.31]
[5]孙辉 金春林 程文迪 房良 王海银.西班牙卫生技术评估的发展应用及启示[J].中国卫生质量管理,2019,26(03):106.[doi:10.13912/j.cnki.chqm.2019.26.3.29]
[6]王海银 丛郦萱 彭颖 王美凤 金春林.我国新医疗技术的定价及支付优化策略探讨[J].中国卫生质量管理,2020,27(01):105.[doi:10.13912/j.cnki.chqm.2020.27.1.27]
[7]程文迪 孙辉 房良 王海银.泰国卫生技术评估机制建设现状及启示[J].中国卫生质量管理,2020,27(01):109.[doi:10.13912/j.cnki.chqm.2020.27.1.28]
[8]邱英鹏赵翔肖月赵羽西.高值医用耗材定义与治理内涵研究[J].中国卫生质量管理,2021,28(05):001.[doi:10.13912/j.cnki.chqm.2021.28.5.01 ]
　QIU Yingpeng,ZHAO Xiang,XIAO Yue.The Definition and Governance Connotation of High Value Medical Consumables[J].Chinese Health Quality Management,2021,28(06):001.[doi:10.13912/j.cnki.chqm.2021.28.5.01 ]
[9]赵羽西邱英鹏肖月.英国高值医用耗材准入及招采管理经验分享：以英格兰为例[J].中国卫生质量管理,2021,28(05):008.[doi:10.13912/j.cnki.chqm.2021.28.5.03 ]
　ZHAO Yuxi,QIU Yingpeng,XIAO Yue.Access and Procurement Management of High Value Medical Consumables in the UK: A Case Study of England[J].Chinese Health Quality Management,2021,28(06):008.[doi:10.13912/j.cnki.chqm.2021.28.5.03 ]
[10]邱英鹏赵羽西赵翔肖月.澳大利亚假体类高值医用耗材医保准入管理经验及启示[J].中国卫生质量管理,2021,28(05):012.[doi:10.13912/j.cnki.chqm.2021.28.5.04 ]
　QIU Yingpeng,ZHAO Yuxi,ZHAO Xiang.Experience in Medical Insurance Access Management of Prosthetic High Value Medical Consumables in Australia and Its Implications[J].Chinese Health Quality Management,2021,28(06):012.[doi:10.13912/j.cnki.chqm.2021.28.5.04 ]

更新日期/Last Update: 2025-06-15